SEP 4, 2026 · PHASE 1 TRIAL
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
ClinicalTrials.gov
Phase 1 study of an mRNA-based cell therapy in chronic granulomatous disease with feasibility and safety as primary outcomes; no results reported in this registry record.
Reported
Planned enrollment25
PhasePhase 1
Primary outcome timeframe3 months